Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (296)	8/25/2000 7:15:33 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 415

Chuckle. Wish I'd never heard of it. Glad you stuck it out, however. Yeah, I looked at the tables. Looks like a good molecule ("479"). Sorry, Tuck, but I just don't (yet) know enough about subtleties. I am enthusiastic that the Daiichi program is now obviously focused. I am concerned that 479 may be cannibalized. Regardless, I'd say that any "munching" would only lead to a short-term, cosmetic hurt on the stock. I am impressed that Iconix is positioning so aggressively in target identification and proteomics. I am concerned that someone is selling, just as ICAAC is coming and as Iconix appears to be ramping up. I don't appreciate it. :-) That's it. I'll go through the abstracts, one-by-one, after I finish a project that I'm working on. Maybe Sunday night, maybe after the open on Monday. Dirt cheap drug discovery infrastructure, and I like Rurka. I'm hoping for good stuff in the independent projects, now that the sector is fluid. Sorry I can't do more right now. Rick